Drug Safety Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects
NCT number | NCT01367873 |
Other study ID # | VIA-3196-01 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | June 2011 |
Est. completion date | October 2011 |
Verified date | August 2023 |
Source | Madrigal Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single-center, randomized, double-blind, placebo-controlled, ascending single-dose study of VIA-3196 to evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects. Study dosing is organized into cohorts corresponding to escalating doses of VIA-3196 or matching placebo.
Status | Completed |
Enrollment | 72 |
Est. completion date | October 2011 |
Est. primary completion date | October 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - The subject must be willing and able to provide written informed consent. - Healthy, non-smoking, males and females between the ages of 18 and 55 years of age (inclusive). - If female, the subject is of non-child bearing potential (i.e., surgically [bilateral oophorectomy, hysterectomy, or tubal ligation] or naturally sterile [>12 consecutive months without menses]). Verify by FSH at screening as appropriate. - Body weight > 50 kg and BMI between 18 and 30 kg/m2 (inclusive). - LDL cholesterol > 85 mg/dL. - No clinically significant abnormal findings on blood pressure, heart rate, physical examination, clinical laboratory tests or 12-lead ECG. Key Exclusion Criteria: - History of thyroid disorder or abnormal thyroid function tests at screening. Repeat testing is allowed at the discretion of the Investigator. - History of unexplained syncope. - History of hepatobiliary disease; or AST, ALT or direct bilirubin greater than the upper limit of reference range at screening. - Positive screening test for HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody. - Abnormal screening ECG: including machine-read QTc >450 msec, QRS >110 msec, intermittent bundle branch block, frequent premature atrial or premature ventricular contractions, or any rhythm other than normal sinus rhythm which is interpreted by the Investigator to be clinically significant. - History of sensitivity to a similar study drug (e.g., Karo Bio KB2115 or Metabasis MB7811), or a history of important drug or other allergy (except for untreated, asymptomatic seasonal allergies at time of dosing). - Sensitivity to thyroid medication. - History of asthma, or intolerance to beta-blockers. - Use of acetaminophen within 7 days before dosing and throughout the study. - History of regular use of tobacco or nicotine containing products within the past 6 months. - Positive urine drug screen or alcohol test at screening. |
Country | Name | City | State |
---|---|---|---|
United States | Cetero Research | Fargo | North Dakota |
Lead Sponsor | Collaborator |
---|---|
Madrigal Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Adverse Events as a measure of safety and tolerability of VIA-3196 | Evaluation will start from predose (Day -1) until the follow-up visit (Day 7 to 11) | up to 12 days | |
Secondary | Plasma concentration of VIA-3196 | Assessed with and without food | 0 to 72 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01425502 -
Data-driven Quality Improvement in Primary Care - Trial
|
N/A | |
Recruiting |
NCT01756183 -
Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer
|
Phase 2 | |
Completed |
NCT01355016 -
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01757860 -
Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01179854 -
Remegal Different Doses in Patients With Refractory Partial Seizures
|
Phase 2 | |
Completed |
NCT00376415 -
A Safety Study of Lessertia Frutescens in Adults.
|
Phase 1 | |
Active, not recruiting |
NCT01722916 -
Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase
|
Early Phase 1 | |
Completed |
NCT01727778 -
Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT01475097 -
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
|
Phase 4 | |
Completed |
NCT01412658 -
Clinical Safety of a Novel Milk Protein Peptide
|
Phase 1 | |
Terminated |
NCT01847222 -
An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATEā¢ in Healthy Volunteers.
|
Phase 1 | |
Unknown status |
NCT01633099 -
Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients
|
Phase 3 | |
Recruiting |
NCT01297842 -
Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections
|
Phase 4 | |
Completed |
NCT01284582 -
Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)
|
Phase 1 | |
Completed |
NCT01556607 -
A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Subjects With Intermittent, or Mild-to-Moderate Persistent, Asthma
|
Phase 1 | |
Completed |
NCT01557270 -
Efficacy and Safety Study of Dexmedetomidine as an Additive to Local Anesthetics in Shoulder Surgery
|
Phase 3 | |
Completed |
NCT01319903 -
Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29
|
Phase 1 | |
Completed |
NCT01271569 -
A Study to Assess the Efficacy and Safety of Fospropofol Disodium
|
Phase 1 | |
Recruiting |
NCT04785027 -
Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis
|
Phase 1/Phase 2 | |
Completed |
NCT01428882 -
Propofol vs. Midazolam-based Balanced Propofol for Nonanesthesiologist Moderate Sedation in Colonoscopy
|
Phase 4 |